Cogent Biosciences Q2 net loss $34.9M; cash $325.6M after June public offering

Cogent Biosciences, Inc.

2022-Q2 EPS reported -$1.39

Cash and equivalents $325.6M at June 30, 2022, up from $191M at March 31, 2022; includes $172.6M from June 2022 public offering, funds operations into 2025.
Net loss $34.9M for Q2 2022 vs $16.5M in Q2 2021; R&D expenses rose to $29.5M from $12.4M on trial costs.
Positive initial bezuclastinib APEX data: all 11 AdvSM patients achieved ≥50% serum tryptase reduction; no edema, cognitive effects or intracranial bleeding.
On-track for further APEX data by end of 2022; SUMMIT and PEAK trial data expected in 1H2023.
Appointed Fang Fang, Ph.D., as VP Biometrics; she brings over 20 years industry experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.